These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 14670643)

  • 1. Differential effects of progestins on hemostasis.
    Schindler AE
    Maturitas; 2003 Dec; 46 Suppl 1():S31-7. PubMed ID: 14670643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis.
    Farris M; Bastianelli C; Rosato E; Brosens I; Benagiano G
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1129-1144. PubMed ID: 28712325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR; Ory H
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exogenous progestins and breast cancer.
    Stanford JL; Thomas DB
    Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects on hemostasis of oral contraceptives containing desogestrel.
    Stubblefield PG
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1047-52. PubMed ID: 8447359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hormonal contraception and thromboembolic disease--pathophysiologic findings and practical recommendations].
    Dulícek P
    Ceska Gynekol; 2001 Sep; 66(5):363-8. PubMed ID: 11732238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormonal contraception].
    Van Cauwenberge JR
    Rev Med Liege; 1992 May; 47(5):221-36. PubMed ID: 1604074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New knowledge in the physiology of hormonal contraceptives.
    Lobo RA; Stanczyk FZ
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks and mechanisms of cardiovascular events in users of oral contraceptives.
    Meade TW
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1646-52. PubMed ID: 3287935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulation and anticoagulation effects of contraceptive steroids.
    Samsioe G
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1523-7. PubMed ID: 8178901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.
    Jespersen J; Petersen KR; Skouby SO
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):396-403. PubMed ID: 2196812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor.
    Herkert O; Kuhl H; Sandow J; Busse R; Schini-Kerth VB
    Circulation; 2001 Dec; 104(23):2826-31. PubMed ID: 11733402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailoring combination oral contraceptives to the individual woman.
    Archer DF; Lasa IL
    J Womens Health (Larchmt); 2011 Jun; 20(6):879-91. PubMed ID: 21631372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacology of newer progestogens.
    Kuhl H
    Drugs; 1996 Feb; 51(2):188-215. PubMed ID: 8808163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolic impact of current estrogen-progestins and cardiovascular consequences].
    Gaspard U; Lambotte R
    Bull Mem Acad R Med Belg; 1991; 146(8-10):334-42; discussion 342-5. PubMed ID: 1815814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.